{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:00:45Z","timestamp":1764745245897,"version":"3.46.0"},"reference-count":70,"publisher":"Touch Medical Media, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<p\/>","DOI":"10.17925\/hi.2021.15.1.42","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T12:10:52Z","timestamp":1628770252000},"page":"42","source":"Crossref","is-referenced-by-count":0,"title":["Sodium\u2013glucose Cotransporter 2 Inhibitors\u2019 Rise to the Backbone of Heart Failure Management: A Clinical Review"],"prefix":"10.17925","volume":"15","author":[{"given":"Namit","family":"Rohant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Advanced Heart Failure and Transplant Cardiology, University of California, San Francisco, CA, USA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie LW","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Inova Heart and Vascular Institute, Falls Church, VA, USA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.\n                      Circ Heart Fail\n                      . 2013;6:606\u201319.","DOI":"10.1161\/HHF.0b013e318291329a"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Jackson SL, Tong X, King RJ, et al. National burden of heart failure events in the United States, 2006 to 2014.\n                      Circ Heart Fail\n                      . 2018;11:e004873.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004873"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Davis RC, Hobbs FD, Lip GY. ABC of heart failure. History and epidemiology.\n                      BMJ\n                      . 2000;320:39\u201342.","DOI":"10.1136\/bmj.320.7226.39"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.\n                      N Engl J Med\n                      . 1986;314:1547\u201352.","DOI":"10.1056\/NEJM198606123142404"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).\n                      N Engl J Med\n                      . 1987;316:1429\u201335.","DOI":"10.1056\/NEJM198706043162301"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology.\n                      Cell Metab\n                      . 2017;26:27\u201338.","DOI":"10.1016\/j.cmet.2017.04.011"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters.\n                      Physiol Rev\n                      . 2011;91:733\u201394.","DOI":"10.1152\/physrev.00055.2009"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Vrhovac I, Balen Eror D, Klessen D, et al. Localizations of Na(+)- D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.\n                      Pflugers Arch\n                      . 2015;467:1881\u201398.","DOI":"10.1007\/s00424-014-1619-7"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Mackenzie B, Loo DD, Panayotova-Heiermann M, et al. Biophysical characteristics of the pig kidney Na+\/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2.\n                      J Biol Chem\n                      . 1996;271:32678\u201383.","DOI":"10.1074\/jbc.271.51.32678"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters.\n                      Physiol Rev\n                      . 1994;74:993\u20131026.","DOI":"10.1152\/physrev.1994.74.4.993"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review.\n                      Diabetes Metab Res Rev\n                      . 2005;21:31\u20138.","DOI":"10.1002\/dmrr.532"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Muscelli E, Astiarraga B, Barsotti E, et al. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.\n                      Diabetologia\n                      . 2016;59:700\u20138.","DOI":"10.1007\/s00125-015-3845-8"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.\n                      J Clin Invest\n                      . 2014;124:499\u2013508.","DOI":"10.1172\/JCI72227"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.\n                      N Engl J Med\n                      . 2007;356:2457\u201371.","DOI":"10.1056\/NEJMoa072761"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Goldfine AB. Assessing the cardiovascular safety of diabetes therapies.\n                      N Engl J Med\n                      . 2008;359:1092\u20135.","DOI":"10.1056\/NEJMp0805758"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors.\n                      Circ Res\n                      . 2018;122:1439\u201359.","DOI":"10.1161\/CIRCRESAHA.117.311588"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.\n                      Diabetes Obes Metab\n                      . 2012;14:83\u201390.","DOI":"10.1111\/j.1463-1326.2011.01517.x"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Mudaliar S, Polidori D, Zambrowicz B, et al. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside.\n                      Diabetes Care\n                      . 2015;38:2344\u201353.","DOI":"10.2337\/dc15-0642"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.\n                      N Engl J Med\n                      . 2015;373:2117\u201328.","DOI":"10.1056\/NEJMoa1504720"},{"key":"ref20","unstructured":"ClinicalTrials.gov. BI 10773 (empagliflozin) cardiovascular outcome event trial in type 2 diabetes mellitus patients (EMPA-REG OUTCOME). ClinicalTrials.gov Identifier: NCT01131676. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01131676 (accessed 22 June 2021)."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes.\n                      N Engl J Med\n                      . 2017;377:644\u201357.","DOI":"10.1056\/NEJMoa1611925"},{"key":"ref22","unstructured":"ClinicalTrials.gov. CANVAS \u2013 canagliflozin cardiovascular assessment study (CANVAS). ClinicalTrials.gov Identifier: NCT01032629. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01032629 (accessed 22 June 2021)."},{"key":"ref23","unstructured":"ClinicalTrials.gov. A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus (CANVAS-R). ClinicalTrials.gov Identifier: NCT01989754. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01989754 (accessed 22 June 2021)."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.\n                      N Engl J Med\n                      . 2019;380:347\u201357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"ref25","unstructured":"ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). ClinicalTrials.gov Identifier: NCT01730534. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01730534 (accessed 22 June 2021)."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes.\n                      N Engl J Med\n                      . 2020;383:1425\u201335.","DOI":"10.1056\/NEJMoa2004967"},{"key":"ref27","unstructured":"ClinicalTrials.gov. Cardiovascular outcomes following ertugliflozin treatment in type 2 diabetes mellitus participants with vascular disease, the VERTIS CV study (MK-8835-004). ClinicalTrials.gov Identifier: NCT01986881. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01986881 (accessed 22 June 2021)."},{"key":"ref28","unstructured":"ClinicalTrials.gov. Specified drug use results survey of Ipragliflozin treatment in type 2 diabetes patients (STELLALONGTERM). ClinicalTrials.gov Identifier: NCT02479399. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02479399 (accessed 15 June 2021)."},{"key":"ref29","unstructured":"ClinicalTrials.gov. The clinical study to assess the effect of the amount of carbohydrate intake and meals differing in glycemic index (GI) in patients treated with a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor. ClinicalTrials.gov Identifier: NCT02500186. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02500186 (accessed 15 June 2021)."},{"key":"ref30","unstructured":"ClinicalTrials.gov. TOFO insulin combination trial. ClinicalTrials.gov Identifier: NCT02201004. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02201004 (accessed 15 June 2021)."},{"key":"ref31","unstructured":"ClinicalTrials.gov. Safety and efficacy of biphasic remogliflozin etabonate in the treatment of type 2 diabetes (BRID). ClinicalTrials.gov Identifier: NCT02537470. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02537470 (accessed 15 June 2021)."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Pereria MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity.\n                      Drugs\n                      . 2019;79:219\u201330.","DOI":"10.1007\/s40265-019-1057-0"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume.\n                      Cardiovasc Diabetol\n                      . 2018;17:6.","DOI":"10.1186\/s12933-017-0658-8"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Riehle C, Abel ED. Insulin signaling and heart failure.\n                      Circ Res\n                      . 2016;118:1151\u201369.","DOI":"10.1161\/CIRCRESAHA.116.306206"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Omar M, Jensen J, Frederiksen PH, et al. Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction.\n                      J Am Coll Cardiol\n                      . 2020;76:2740\u201351.","DOI":"10.1016\/j.jacc.2020.10.005"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Marton A, Kaneko T, Kovalik JP, et al. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.\n                      Nat Rev Nephrol\n                      . 2021;17:65\u201377.","DOI":"10.1038\/s41581-020-00350-x"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Sano M, Takei M, Shiraishi Y, et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys.\n                      J Clin Med Res\n                      . 2016;8:844\u20137.","DOI":"10.14740\/jocmr2760w"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.\n                      Biopharm Drug Dispos\n                      . 2014;35:391\u2013404.","DOI":"10.1002\/bdd.1909"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Bosch A, Ott C, Jung S, et al. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.\n                      Cardiovasc Diabetol\n                      . 2019;18:44.","DOI":"10.1186\/s12933-019-0839-8"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.\n                      Cardiovasc Diabetol\n                      . 2019;18:15.","DOI":"10.1186\/s12933-019-0816-2"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction.\n                      N Engl J Med\n                      . 2019;381:1995\u20132008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"ref42","unstructured":"ClinicalTrials.gov. Study to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure (DAPA-HF). ClinicalTrials.gov Identifier: NCT03036124. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03036124 (accessed 22 June 2021)."},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure.\n                      N Engl J Med\n                      . 2020;383:1413\u201324.","DOI":"10.1056\/NEJMoa2022190"},{"key":"ref44","unstructured":"ClinicalTrials.gov. Empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction (EMPEROR-Preserved). ClinicalTrials.gov Identifier: NCT03057951. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951 (accessed 22 June 2021)."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure.\n                      N Engl J Med\n                      . 2021;384:117\u201328.","DOI":"10.1056\/NEJMoa2030183"},{"key":"ref46","unstructured":"ClinicalTrials.gov. Effect of sotagliflozin on cardiovascular events in patients with type 2 diabetes post worsening heart failure (SOLOIST-WHF Trial). ClinicalTrials.gov Identifier: NCT03521934. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03521934 (accessed 15 June 2021)."},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial.\n                      Circulation\n                      . 2019;140:1463\u201376.","DOI":"10.1161\/CIRCULATIONAHA.119.042929"},{"key":"ref48","unstructured":"ClinicalTrials.gov. Are the \u201cCardiac Benefits\u201d of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4). (EMPA-TROPISM). ClinicalTrials.gov Identifier: NCT03485222. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03485222 (accessed 22 June 2021)."},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction.\n                      J Am Coll Cardiol\n                      . 2021;77:243\u201355.","DOI":"10.1016\/j.jacc.2020.11.008"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF).\n                      Circulation\n                      . 2021;143:516\u201325.","DOI":"10.1161\/CIRCULATIONAHA.120.052186"},{"key":"ref51","unstructured":"ClinicalTrials.gov. Studies of empagliflozin and its cardiovascular, renal and metabolic effects (SUGAR-DM-HF). ClinicalTrials.gov Identifier: NCT03485092. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03485092 (accessed 22 June 2021)."},{"key":"ref52","unstructured":"ClinicalTrials.gov. Dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure. (DELIVER). ClinicalTrials.gov Identifier: NCT03619213. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619213 (accessed 15 June 2021)."},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.\n                      N Engl J Med\n                      . 2019;380:2295\u2013306.","DOI":"10.1056\/NEJMoa1811744"},{"key":"ref54","unstructured":"54. ClinicalTrials.gov. Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE). ClinicalTrials.gov Identifier: NCT02065791. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02065791 (accessed 15 June 2021)."},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease.\n                      N Engl J Med\n                      . 2020;383:1436\u201346.","DOI":"10.1056\/NEJMoa2024816"},{"key":"ref56","unstructured":"ClinicalTrials.gov. A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD). ClinicalTrials.gov Identifier: NCT03036150. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03036150 (accessed 15 June 2021)."},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease.\n                      N Engl J Med\n                      . 2021;384:129\u201339.","DOI":"10.1056\/NEJMoa2030186"},{"key":"ref58","unstructured":"ClinicalTrials.gov. Effect of sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes and moderate renal impairment who are at cardiovascular risk (SCORED). ClinicalTrials.gov Identifier: NCT03315143. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03315143 (accessed 15 June 2021)."},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines.\n                      Circulation\n                      . 2013;128:1810\u201352.","DOI":"10.1161\/CIR.0b013e31829e8807"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure.\n                      N Engl J Med\n                      . 2014;371:993\u20131004.","DOI":"10.1056\/NEJMoa1409077"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.\n                      N Engl J Med\n                      . 2002;346:877\u201383.","DOI":"10.1056\/NEJMoa013474"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.\n                      N Engl J Med\n                      . 2004;350:2140\u201350.","DOI":"10.1056\/NEJMoa032423"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Anand IS, Carson P, Galle E, et al. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial.\n                      Circulation\n                      . 2009;119:969\u201377.","DOI":"10.1161\/CIRCULATIONAHA.108.793273"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.\n                      Lancet\n                      . 2010;376:875\u201385.","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction.\n                      N Engl J Med\n                      . 2020;382:1883\u201393.","DOI":"10.1056\/NEJMoa1915928"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure.\n                      N Engl J Med\n                      . 1997;336:525\u201333.","DOI":"10.1056\/NEJM199702203360801"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020.\n                      Eur Heart J\n                      . 2015;36:657\u201368.","DOI":"10.1093\/eurheartj\/ehu385"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Teerlink JR, Diaz R, Felker GM, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure.\n                      N Engl J Med\n                      . 2021;384:105\u201316.","DOI":"10.1056\/NEJMoa2025797"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee.\n                      J Am Coll Cardiol\n                      . 2021;77:772\u2013810.","DOI":"10.1016\/j.jacc.2020.11.022"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Palmer BF, Clegg DJ. Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy.\n                      Clin J Am Soc Nephrol\n                      . 2021:CJN.17621120.","DOI":"10.2215\/CJN.17621120"}],"container-title":["Heart International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchcardio.com\/heart-failure\/journal-articles\/sodium-glucose-cotransporter-2-inhibitors-rise-to-the-backbone-of-heart-failure-management-a-clinical-review\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:58:27Z","timestamp":1764745107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchcardio.com\/heart-failure\/journal-articles\/sodium-glucose-cotransporter-2-inhibitors-rise-to-the-backbone-of-heart-failure-management-a-clinical-review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"alternative-id":["HI.2021.15.1.42"],"URL":"https:\/\/doi.org\/10.17925\/hi.2021.15.1.42","relation":{},"ISSN":["2036-2579"],"issn-type":[{"type":"print","value":"2036-2579"}],"subject":[],"published":{"date-parts":[[2021]]}}}